Japanese Phase I study of JR-441
Latest Information Update: 23 Sep 2024
At a glance
- Drugs JR-441 (Primary)
- Indications Mucopolysaccharidosis III
- Focus Adverse reactions
- 23 Sep 2024 New trial record
- 03 Sep 2024 The regulatory review by the Pharmaceuticals and Medical Devices Agency (PMDA) for the clinical trial notification for the Phase I study of JR-441 in individuals with mucopolysaccharidosis type IIIA (MPS IIIA; Sanfilippo syndrome type A), has been completed, and the clinical development program is completing.